ImmunoPrecise Antibodies (IPA) has reported that preliminary, preclinical data from a study of its TATX-03 PolyTope antibody cocktail programme demonstrated complete clearance of detectable replication-competent virus from the lungs and throat of Covid-19 infected hamsters.

The SARS-CoV-2 PolyTope monoclonal therapies can potentially provide protection against mutagenic escape to provide efficacy for every patient, variant and strain of the virus.

TATX-03 is a combination of four proprietary monoclonal antibodies directed against different SARS-CoV-2 spike protein region.

According to results from the preclinical study using a SARS-CoV-2 hamster model, treatment with IPA’s TATX-03 antibody cocktail offered strong robust anti-viral effects against SARS-CoV-2 in prophylactic (preventative), as well as treatment settings.

In a therapeutic setting, a single dose of the antibody cocktail cleared the lungs of detectable replication-competent virus in all SARS-CoV-2-infected hamsters by day four post-infection.

In the prophylactic setting, a single dose of the antibody cocktail was administered 24 hours before infecting hamsters with a SARS-CoV-2 variant.

A reduction of replication-competent virus titer to undetectable levels in the lungs of four out of five hamsters by day four was observed while one animal had virus levels just above the lowest detection level.

IPA noted that two of the three antibodies tested from the TATX-03 cocktail were not affected by SARS-CoV-2 variants, including the South African and UK ones.

ImmunoPrecise Antibodies SARS-CoV-2 global programme director Dr Ilse Roodink said: “This important preclinical study shows that TATX-03 not only protected against but effectively treated, a high dose of SARS-CoV-2 variant infection in hamsters, further supporting the advancement of TATX-03.”

During the second quarter of this year, IPA plans to carry out the final IND-enabling studies, including non-human primate, dose-dependent evaluation of the TATX-03 antibody cocktail.

The company anticipates that these studies will deliver the final, essential preclinical data points required for supporting TATX-03’s potential clinical evaluation.